Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country
ASSEMBLY ELEVATES VIVIAN MOK TO SVP & MANAGING DIRECTOR FOR NORTH ASIA
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
Team T5 Applauded by Frost & Sullivan for Deeply and Effectively Monitoring Regional Adversaries and Incidents
Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab
Hangzhou Hosts Second Liangzhu Forum with Global Cultural Leaders
Global Times: Dialogue across Yangtze, Rhine, Danube bridges mutual learning between China and Europe
XREX CISO Leads DeFiHackLabs To Victory at SCAN 2024, the World's First Digital Asset Tracking Challenge
